Sep 16, 2021, 11:20 PM
New evidence for memantine and benperidol (including a thorough QT study, review of case reports, and drug label changes) does not indicate that memantine or benperidol are associated with QT prolongation under normal conditions of use. Therefore these two drugs have been removed from the Possible Risk of Torsades de pointes (TdP) category. Also, diltiazem has been added to the Conditional Risk of TdP category.
Jul 7, 2021, 10:48 AM
Recent warnings that certain manufacturing lots of several very important medicines have been recalled because the have been found to contain higher than acceptable levels of chemicals known to cause cancer in animals.
Jun 2, 2021, 12:46 AM
If you suspect that you have COVID-19, it is essential that you contact your healthcare provider to confirm the diagnosis and to determine if you are at high-risk of requiring hospitalization. These treatments can reduce the severity of COVID-19 in adults and children and could be life-saving if administered early. Go to the website provided by the US Department of Health and Human Services to learn more…
May 11, 2021, 1:46 AM
The SADS Foundation just released a COVID-19 Vaccine statement that recommends that all individuals with SADS conditions receive a vaccination. Michael J. Ackerman, MD, PhD, director of the Long QT Syndrome Clinic and professor of medicine, pediatrics, and molecular pharmacology at the Mayo Clinic College of Medicine, Rochester, Minnesota and Chair, Board of Trustees, SADS Foundation said, "I've told all of my patients and every genetic heart patient we talk with at the SADS Foundation (Long QT syndrome, CPVT, Brugada syndrome, ARVC, etc.). If you are 16 years or older, you can get the vaccine, you should get the vaccine, it is safe for your heart."
May 4, 2021, 10:32 PM
Three new drugs have been added and one removed from the Possible Risk of TdP category for the QTdrugs list. Two drugs used for prostate cancer (Bicalutamide and Relugolix) and an antibiotic (Linezolid) have been added to the Possible Risk category. The drug combination product, Moexipril and Hydrocholorthiazide, was removed from the Possible Risk of TdP category due to labelling changes and a lack of supporting evidence of an effect on the QT interval.
Apr 6, 2021, 7:00 AM
Today, Tuesday April 6th, AZCERT, the makers of CredibleMeds and MedSafety Scan, will participate in "Arizona Gives Day," a statewide online charitable giving event to inspire people to give generously to nonprofit organizations who make our state and world a healthier and more vital place to live.
Mar 31, 2021, 12:00 PM
Two drugs newly marketed in the US, Ponesimod for treatment of multiple sclerosis and Voclosporin for treatment of lupus nephritis, have been added to the QTdrugs list in the Possible Risk of TdP category. They will also be added to the list of Drugs to Avoid for patients with congenital long QT syndrome.
Multi-Stakeholder Collaboration Offers Free Educational Resource for QTc Risk Score and Clinical Decision Support
Jan 25, 2021, 12:43 PM
AZCERT is proud to announce its participation in a multi-stakeholder collaboration with scientists from the University of Arizona, University of Utah, Purdue University and Banner Health to develop and disseminate a clinical decision support program designed to assist the safe use of QT prolonging drugs. This work has been funded by grants from the Agency for Healthcare Research and Quality (AHRQ) and the US Food and Drug Administration (FDA).
Dec 18, 2020, 12:47 PM
The COVID-19 vaccines that are rolling out across the US and the world are our only hope for ending the global pandemic. While other precautions, like covering your mouth and nose with a mask and staying at least 6 feet away from others will still need to be adhered to — for the time being — in order to stop the pandemic it is imperative that we use every tool available.
Dec 17, 2020, 12:53 PM
The Torsades risk category for Sertindole, a drug for the treatment of schizophrenia, has changed....